BTX - Brooklyn ImmunoTherapeutics Inc Ordinary Shares (Healthcare: Biotechnology) Projected Earnings Date: 2022-06-13    (Delayed quote data   2026-02-10)
Last
 6.73		 Change
 ⇑ +0.03   (+0.37%)		 Volume
  658,226
Open
 6.73		 High
 6.78		 Low
 6.71
8EMA (Daily)
 6.61		 40EMA (Daily)
 6.69		 50EMA (Daily)
 6.70		 STO (Daily)
 42.899		 MACD Hist (Daily)
 0.008
8EMA (Weekly)
 6.707		 40EMA (Weekly)
 6.39		 50EMA (Weekly)
 6.14		 STO (Weekly)
 57.282		 MACD Hist (Weekly)
 -0.008
Company Profile
Brooklyn ImmunoTherapeutics Inc is a clinical stage biopharmaceutical company. It is developing IRX-2, a novel hd-IL-2 -based therapy, to treat patients with cancer. IRX-2 delivers hd-IL-2 and other key cytokines to potentially restore immune function in the tumor microenvironment, enabling the immune system to attack cancer cells.
optionchance optionchance
⇒ Home | Chart and Research | Education | About Us  

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.

Questions or Comments: support@optionchance.com
Copyright © 2026 OptionChance.com